UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported)  November 8, 2005

 

 

 

SONUS PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware

 

0-26866

 

95-4343413

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No)

 

 

22026 20th Avenue S.E., Bothell, Washington   98021

(Address of principal executive offices)

 

 

(425) 487-9500

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

 

o

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

 

o

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

 

o

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

 


 

Item 2.02               Results of Operations and Financial Condition.

 

On November 8, 2005, Sonus Pharmaceuticals, Inc. issued a press release announcing its financial results for the fiscal quarter ended September 30, 2005.  A copy of the press release making this announcement along with a transcript of the conference call are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.  The press release and the conference call transcript shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933.

 

 

Item 9.01               Financial Statements and Exhibits.

 

Exhibit 99.1                                                      Press Release, dated November 8, 2005, issued by Sonus Pharmaceuticals, Inc.

 

Exhibit 99.2                                                      Transcript of Sonus Pharmaceuticals, Inc. third quarter 2005 conference call.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

SONUS PHARMACEUTICALS, INC.

 

 

 

 

 

 

 

 

 

 

 

 

Date: November 14, 2005

 

By:

/s/ Alan Fuhrman

 

 

 

Alan Fuhrman

 

 

 

Senior Vice President and Chief Financial Officer

 

3


 

EXHIBIT INDEX

 

 

 

Exhibit No.

 

Description

 

 

 

Exhibit 99.1

 

Press Release, dated November 8, 2005, issued by Sonus Pharmaceuticals, Inc.

 

 

 

Exhibit 99.2

 

Transcript of Sonus Pharmaceuticals, Inc. third quarter 2005 conference call.

 

 

 

 

4